FMP

FMP

Enter

YMAB - Y-mAbs Therapeutics, Inc.

Profile of Y-mAbs Therapeutics, Inc.(YMAB), Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development

photo-url-https://financialmodelingprep.com/image-stock/YMAB.png

Y-mAbs Therapeutics, Inc.

YMAB

NASDAQ

16.26 USD

-0.24 (-1.48%)

About

ceo

Mr. Michael Rossi

sector

Healthcare

industry

Biotechnology

website

https://www.ymabs.com

exchange

NASDAQ

Description

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

CIK

0001722964

ISIN

US9842411095

CUSIP

984241109

Address

230 Park Avenue

Phone

646 885 8505

Country

US

Employee

100

IPO Date

Sep 21, 2018

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep